Cancer Letters
Volume 290, Issue 2 , Pages 174-181 , 28 April 2010

Human melanoma cells expressing the αvβ3 integrin are partially protected from necrotic cell death induced by dynamic matrix detachment

  • K. Tzukert

      Affiliations

    • Department of Medicine, En Kerem Campus, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
    • ,
  • N. Shimony

      Affiliations

    • Department of Medicine, En Kerem Campus, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
    • ,
  • L. Krasny

      Affiliations

    • Department of Medicine, En Kerem Campus, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
    • ,
  • S. Urieli-Shoval

      Affiliations

    • Department of Hematology, Mount Scopus Campus, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
    • ,
  • R. Gorodetsky

      Affiliations

    • Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
    • ,
  • I. Avrahami

      Affiliations

    • Afeka Tel-Aviv College of Engineering, Tel-Aviv, Israel
    • ,
  • D.M. Nettelbeck

      Affiliations

    • Helmholtz-University Group Oncolytic Adenoviruses, DKFZ and Department of Dermatology, Heidelberg University Hospital, Heidelberg, Germany
    • ,
  • Y.S. Haviv

      Affiliations

    • Department of Medicine, En Kerem Campus, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
    • Corresponding Author InformationCorresponding author. Address: Department of Medicine, Hadassah-Hebrew University Medical Center, PO Box 12000, Jerusalem 91120, Israel. Tel.: +972 26776881; fax: +972 26446335.

Received 8 December 2008 ,Revised 29 August 2009 ,Accepted 7 September 2009.

References 

  1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  2. Shimony N, Avrahami I, Gorodetsky R, Elkin G, Tzukert K, Zangi L, et al. A 3-D rotary renal and mesenchymal stem cell culture model unveils cell death mechanisms induced by matrix deficiency and low shear stress. Nephrology Dialysis Transplantation. 2008;23:2071–2080
  3. Tzukert K, Gorodestky R, Avrahami I, Krasny L, Shimony N, Elkin G, et al. A novel dynamic matrix detachment model reveals a shift from apoptosis to necrosis in melanoma cells. Cancer Letters. 2008;272(2):345–354
  4. Rupp PA, Little CD. Integrins in vascular development. Circulation Research. 2001;89:566–572
  5. Geiger B, Bershadsky A, Pankov R, Yamada KM. Transmembrane extracellular matrix–cytoskeleton crosstalk. Nature Reviews Molecular Cell Biology. 2001;2:793–805
  6. Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Frontiers in Bioscience. 2005;10:2986–3001
  7. Hecker TP, Gladson CL. Focal adhesion kinase in cancer. Frontiers in Bioscience. 2003;8:S705–S714
  8. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the alpha-v-beta-3 integrin – adhesion mechanism for transformed glial-cells. Journal of Clinical Investigation. 1991;88:1924–1932
  9. Nip J, Shibata H, JLoskutoff D, Cheresh DA, Brodt P. Human-melanoma cells derived from lymphatic metastases use integrin alpha-v-beta-3 to adhere to lymph-node vitronectin. Journal of Clinical Investigation. 1992;90:1406–1413
  10. Feldinghabermann B, Mueller BM, Romerdahl CA, Cheresh DA. Involvement of integrin alpha-v gene-expression in human-melanoma tumorigenicity. Journal of Clinical Investigation. 1992;89:2018–2022
  11. Albelda SM, Mette SA, Elder DE, Stewart RM, Damjanovich L, Herlyn M, et al. Integrin distribution in malignant-melanoma – association of the beta-3-subunit with tumor progression. Cancer Research. 1990;50:6664–6757
  12. Montgomery AMP, Reisfeld RA, Cheresh DA. Integrin-alpha-v-beta-3 rescues melanoma-cells from apoptosis in 3-dimensional dermal collagen. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:8856–8860
  13. Brassard DL, Maxwell E, Malkowski M, Nagabhushan TL, Kumar CC, Armstrong L. Integrin alpha-v-beta3-mediated activation of apoptosis. Experimental Cell Research. 1999;251:33–45
  14. Zhang Y, Lu H, Dazin P, Kapila Y. Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis – fibronectin and integrin alpha(v)-mediate survival signals through focal adhesion kinase. Journal of Biological Chemistry. 2004;279:48342–48349
  15. Folkman J, Moscona A. Role of cell-shape in growth-control. Nature. 1978;273:345–349
  16. Frisch SM, Francis H. Disruption of epithelial cell–matrix interactions induces apoptosis. Journal of Cell Biology. 1994;124:619–662
  17. Frisch SM, Vuori K, Ruoslahti E, ChanHui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. Journal of Cell Biology. 1996;134:793–799
  18. Frisch SM, Ruoslahti E. Integrins and anoikis. Current Opinion in Cell Biology. 1997;9:701–706
  19. Meredith JE, Fazeli B, Schwartz MA. The extracellular-matrix as a cell-survival factor. Molecular Biology of the Cell. 1993;4:953–961
  20. Lee Y, Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. Journal of Biological Chemistry. 1999;274:19792–19798
  21. Englert RP, Shacter E. Distinct modes of cell death induced by different reactive oxygen species – amino acyl chloramines mediate hypochlorous acid-induced apoptosis. Journal of Biological Chemistry. 2002;277:20518–20526
  22. Schwartz MA, McRoberts K, Coyner M, Andarawewa KL, Frierson HF, Sanders JM, et al. Integrin agonists as adjuvants in chemotherapy for melanoma. Clinical Cancer Research. 2008;14:6193–6197
  23. Lewis JM, Truong TN, Schwartz MA. Integrins regulate the apoptotic response to DNA damage through modulation of p53. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:3627–3632
  24. Tzima E, del Pozo MA, Shattil SJ, Chien S, Schwartz MA. Activation of integrins in endothelial cells by fluid shear stress mediates Rho-dependent cytoskeletal alignment. EMBO Journal. 2001;20:4639–4647
  25. Elicieri B, Stromblad S, Cheresh D. Integrin alpha-v-beta-3-ligation requirement for a sustained MAP kinase signal essential for angiogenesis. FASEB Journal. 1997;11:A1290
  26. Frisch SM, Screaton RA. Anoikis mechanisms. Current Opinion in Cell Biology. 2001;13:555–562
  27. Eckert LB, Repasky GA, Ulku AS, McFall A, Zhou H, Sartor CI, et al. Involvement of RAS activation in human breast cancer cell signaling invasion and anoikis. Cancer Research. 2004;64:4585–4592
  28. Diaz-Montero CM, Wygant JN, McIntyre BW. PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires SRC activation. European Journal of Cancer. 2006;42:1491–1500
  29. Fukazawa H, Noguchi K, Murakami Y, Uehara Y. Mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Molecular Cancer Therapeutics. 2002;1:303–309
  30. Collins NL, Reginato MJ, Paulus JK, Sgroi DC, LaBaer J, Brugge JS. G(1)/S cell cycle arrest provides anoikis resistance through ERK-mediated BIM suppression molecular and cellular biology. 2005;25:5282–5291
  31. Kairouz-Wahbe R, Biliran H, Luo X, Khor I, Wankell M, Besch-Williford C, et al. Anoikis effector Bit1 negatively regulates ERK activity. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:1528–1532
  32. Khwaja A, RodriguezViciana P, Wennstrom S, Warne PH, Downward J. Matrix adhesion and RAS transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO Journal. 1997;16:2783–2793
  33. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochemical Journal. 2007;404:15–21
  34. Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AMP, et al. Integrin alpha-v-beta-3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Research. 1999;59:2724–2730

PII: S0304-3835(09)00574-6

doi: 10.1016/j.canlet.2009.09.007

Cancer Letters
Volume 290, Issue 2 , Pages 174-181 , 28 April 2010

Article Tools

* Image Usage & Resolution